Table: Sumitomo Pharma -Q1 group results (IFRS)

Sumitomo Pharma

31/07/2023 07:30

Jul 31 (Reuters)- 
              Sumitomo Pharma Co., Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                 3 months ended      3 months ended        Year to   
                Jun 30, 2023        Jun 30, 2022       Mar 31, 2024  
                   LATEST             YEAR-AGO           COMPANY     
                   RESULTS             RESULT            FORECAST    
  Sales             75.69              159.88             362.00     
                 (-52.7 pct)         (+21.9 pct)       (-34.8 pct)   
  Operating      loss 51.57             14.61           loss 78.00   
                                     (+75.9 pct)                     
  Pretax
  Net            loss 38.87             31.11           loss 80.00   
                                    (+547.8 pct)                     
  EPS Basic    loss 97.82 yen         78.30 yen      loss 201.36 yen 
  Ann Div                             21.00 yen            NIL       
  -Q2 Div                             14.00 yen            NIL       
  -Q4 Div                             7.00 yen             NIL       
 
  NOTE - Sumitomo Pharma Co., Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4506.T